Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aegle marmelos leaf extract is a botanical preparation derived from the leaves of *Aegle marmelos*, a medicinal plant used in traditional medicine. In the provided preclinical literature, it was studied as an orally administered plant extract for cognitive impairment in a scopolamine-induced rat model of Alzheimer's disease, where it showed dose-dependent improvement in memory-related outcomes and preservation of hippocampal synaptophysin and dendritic spine density. Its putative mechanism is not fully defined, but the cited study and background suggest acetylcholinesterase inhibitory activity together with broader neuroprotective effects on synaptic integrity. It is best characterized as an investigational botanical extract or nutraceutical-style natural product rather than a conventional single-agent pharmaceutical drug with a standardized developer-led clinical program.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aegle marmelos leaf extract.